Buyers Want 1st Circ. To Rethink Nexium Pay-For-Delay Suit

Retailers and indirect purchasers of heartburn medication Nexium on Monday asked the First Circuit for a rehearing of its November decision declining to revive a pay-for-delay class action against AstraZeneca PLC...

Already a subscriber? Click here to view full article